Read more
4:11 PM · 6 March 2025

Hims & Hers drops after court ruling on FDA decision regarding Zepbound📉

Hims & Hers Health
Stocks
HIMS.US, Hims & Hers Health Inc
-
-

Hims & Hers (HIMS.US), a company specializing in selling compounded medications, is experiencing an approximately 8% decline today following a court's rejection of a preliminary injunction request concerning the FDA's decision to remove Zepbound (Eli Lilly's weight-loss drug) from the shortage list.

Under U.S. law, companies can offer copycat versions of brand-name drugs as long as they remain on the shortage list. Therefore, the FDA’s decision has significantly limited the operations of such companies, leading the Outsourcing Facilities Association (OFA) to file a lawsuit against the FDA.

The court’s decision to deny OFA’s request for a preliminary injunction, which would have allowed companies to continue producing lower-cost drug alternatives, is a negative signal for the sector. This is reflected in Hims & Hers' stock price, which has dropped to its lowest level since early February 2025.

The FDA’s decision already led to an 11% decline in Hims & Hers’ stock in December. Today, its shares are down nearly 8%.Source: xStation


 

31 October 2025, 7:08 PM

Daily summary: Sentiments on Wall Street stall at the end of the week🗽US Dollar gains

31 October 2025, 4:08 PM

AbbVie near 1-month low after earnings report 📉

31 October 2025, 3:14 PM

Wall Street optimism tempers amid falling odds of December Fed rate cut

31 October 2025, 11:25 AM

DE40: Decline of sentiment in Europe

Join over 2 000 000 XTB Group Clients from around the world

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits